Follow the people · Insider
Avraham Gabay
Avraham Gabay files insider transactions with the SEC as a director of Lifeward (LFWD). We hold 1 disclosed purchase or sale filed since 27 June 2019, 1 of them in the last 90 days.
- Files forLFWD
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure24 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 20 August 2026 — 20 August 2026Director · Lifeward (LFWD)1 Form 4 line · source: SEC Form 4
- Filed 17 June 2019 — 1 July 2026Chief Financial Officer · Oramed Pharmaceuticals (ORMP)22 Form 4 lines · source: SEC Form 4
Everything they disclosed
23 entries, newest first — one per disclosure report, one per Form 4 line- was granted 13,643 shares of LifewardSEC Form 424 August 2026Ordinary Shares, no par value per share · traded 20 August 2026 · filed 24 August 2026
- ▼ sold on the open market 73,360 shares of Oramed PharmaceuticalsSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- was granted 95,889 shares of Oramed PharmaceuticalsSEC Form 418 March 2026Common Stock · traded 17 March 2026 · filed 18 March 2026
- was granted 95,889 shares of Oramed PharmaceuticalsSEC Form 418 March 2026Common Stock · traded 17 March 2026 · filed 18 March 2026
- exercised options over 19,000 shares of Oramed PharmaceuticalsSEC Form 429 January 2026Common Stock · traded 22 January 2026 · filed 29 January 2026
- exercised options over 19,000 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 429 January 2026Performance Stock Units · traded 22 January 2026 · filed 29 January 2026
- exercised options over 19,000 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 429 January 2026Performance Stock Units · traded 22 January 2026 · filed 29 January 2026
- exercised options over 19,000 shares of Oramed PharmaceuticalsSEC Form 429 January 2026Common Stock · traded 22 January 2026 · filed 29 January 2026
- was granted 81,216 shares of Oramed PharmaceuticalsSEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- was granted 115,000 shares of Oramed PharmaceuticalsSEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- was granted 19,000 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 42 January 2026Performance Stock Units · traded 31 December 2025 · filed 2 January 2026
- was granted 19,000 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 42 January 2026Performance Stock Units · traded 31 December 2025 · filed 2 January 2026
- was granted 81,216 shares of Oramed PharmaceuticalsSEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- was granted 115,000 shares of Oramed PharmaceuticalsSEC Form 42 January 2026Common Stock · traded 31 December 2025 · filed 2 January 2026
- was granted 34,000 shares of Oramed PharmaceuticalsSEC Form 411 February 2025Common Stock · traded 11 February 2025 · filed 11 February 2025
- was granted 42,000 shares of Oramed PharmaceuticalsSEC Form 411 February 2025Common Stock · traded 11 February 2025 · filed 11 February 2025
- was granted 188,000 shares of Oramed PharmaceuticalsSEC Form 46 January 2025Common Stock · traded 2 January 2025 · filed 6 January 2025
- was granted 30,000 shares of Oramed PharmaceuticalsSEC Form 48 November 2024Common Stock · traded 7 November 2024 · filed 8 November 2024
- was granted 140,040 shares of Oramed PharmaceuticalsSEC Form 421 June 2024Common Stock · traded 21 June 2024 · filed 21 June 2024
- was granted 40,000 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 48 February 2021Stock Option (right to buy) · traded 3 February 2021 · filed 8 February 2021
- returned to the issuer 33,146 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 416 September 2019Stock Option (right to buy) · traded 17 June 2019 · filed 16 September 2019
- was granted 33,146 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 416 September 2019Stock Option (right to buy) · traded 12 September 2019 · filed 16 September 2019
- was granted 33,146 shares of Oramed Pharmaceuticals (a derivative holding)SEC Form 427 June 2019Stock Option (right to buy) · traded 17 June 2019 · filed 27 June 2019
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.